Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Grzegorz S. Nowakowski, MD, Mayo Clinic
Advertisement
Articles by Grzegorz S. Nowakowski, MD, Mayo Clinic
Advertisement
Latest Updated Articles
CAR T in Transplant-Eligible and Transplant-Ineligible DLBCLPublished: September 22nd 2020 | Updated:
RE-MIND Study in R/R DLBCLPublished: September 22nd 2020 | Updated:
Treatment of R/R DLBCL: Beyond CAR T TherapyPublished: September 22nd 2020 | Updated:
Standard of Care for Relapsed/Refractory DLBCLPublished: September 22nd 2020 | Updated:
Phase 2B SADAL Trial in R/R DLBCLPublished: September 22nd 2020 | Updated:
L-MIND Study in R/R DLBCLPublished: September 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5